All In Biotech

Drug Trial Radar · NCT06491446

Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts

A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 141 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

141

Actual

Start

Mar 27, 2024

Primary completion

Oct 17, 2025

Study completion Apr 20, 2026

Sponsor

Lead sponsor
Antiva BiosciencesIndustry
Sponsor type
Industry
First posted
Jul 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 25 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a blinded study to assess safety, tolerability, and efficacy of ABI-2280 vaginal inserts in participants diagnosed with persistent cervical hrHPV infection. This study will have up to 11 cohorts with various dose strengths and regimens. Each cohort will start with a sentinel cohort of 8 participants. Sentinel cohorts may be expanded to include an additional up to 32 participants to provide additional proof of concept data to further understanding of benefit/risk of a given dose/dose regimen.

Conditions

  • Human Papillomavirus Infection

Interventions

  • ABI-2280Drug

    Different strength of ABI 2280 will be administered in different cohorts. Other: Placebo Matching placebo will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. For sentinel cohorts: Incidence and Severity of Adverse EventsTime frame: Week 24
  2. For fully expanded cohorts, including sentinel: Clearance of persistent cervical hrHPV infection as defined by the absence of all hrHPV genotypes present at baselineTime frame: Week 12

Locations

24 sites in 4 countries. Site status is shown where the registry gives one.

  • Emeritus Research Camberwell

    Camberwell, Australia

  • Holdsworth House Medical Practice

    Darlinghurst, Australia

  • KIMR

    Nedlands, Australia

  • The Royal Women's Hospital

    Parkville, Australia

  • Emeritus Research Sydney

    Sydney, Australia

  • AusTrials Taringa

    Taringa, Australia

  • AusTrials Wellers Hill

    Tarragindi, Australia

  • PARC Clinical Research, Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • International Cancer Institute

    Eldoret, Kenya

  • Victoria Cancer Care & Research Centres

    Kisii, Kenya

  • Kenya Medical Research Institute (KEMRI) - RCTP Kisumu

    Kisumu, Kenya

  • Victoria Biomedical Research Institute

    Kisumu, Kenya

  • Arke Estudios Clinicos S.A. De C.V.

    Cuauhtémoc, Mexico

  • Centro Oncologico Internacional

    Mexico City, Mexico

  • Unidad de Medicina Especializada SMA

    Querétaro, Mexico

  • FAICIC S. de R.L. de C.V.

    Veracruz, Mexico

  • Waitemata Clinical Research Ltd

    Birkenhead, New Zealand

  • P3 Research Dunedin

    Dunedin, New Zealand

  • P3 Research Hawke's Bay

    Hastings, New Zealand

  • P3 Research Lower Hutt

    Lower Hutt, New Zealand

  • Pacific Clinical Trials Network - Tasman

    Nelson, New Zealand

  • P3 Research Kapiti

    Paraparaumu, New Zealand

  • Lakeland Clinical Trials

    Rotorua, New Zealand

  • Clinical Horizons New Zealand

    Tauranga, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.